Recent studies have shown that febuxostat, a novel non‐purine selective inhibitor of xanthine oxidase (XO), is more effective than allopurinol in lowering the uric acid levels in patients with hyperuricemia and gout.3, 4. Here, XDH is linked to hyperuricemia.